Dr. Pouliot completed a doctoral degree in Human Physiology at the University of Montreal and a fellowship at McGill University on multidrug resistance in cancer. With broad experience in clinical development, he worked on numerous phase I – III programs leading to innovative drug approvals, including imatinib in chronic myelogenous leukemia, temozolomide in brain tumors, pembrolizumab and cemiplimab in skin and lung cancer. Over the years, he fostered numerous academia-industry collaborations and investigator-driven initiatives across the Americas, Europe, and Asia. At Regeneron Pharmaceuticals, he leads the global medical affairs team in lung cancer and other solid tumors.